BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 27607895)

  • 1. Rituximab therapy in primary Sjögren's syndrome with interstitial lung disease: a retrospective cohort study.
    Chen MH; Chen CK; Chou HP; Chen MH; Tsai CY; Chang DM
    Clin Exp Rheumatol; 2016; 34(6):1077-1084. PubMed ID: 27607895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary manifestations of Sjögren's syndrome.
    Shi JH; Liu HR; Xu WB; Feng RE; Zhang ZH; Tian XL; Zhu YJ
    Respiration; 2009; 78(4):377-86. PubMed ID: 19390161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren's syndrome-related interstitial lung disease in a Chinese population.
    Dong X; Zhou J; Guo X; Li Y; Xu Y; Fu Q; Lu Y; Zheng Y
    Clin Rheumatol; 2018 Nov; 37(11):2981-2988. PubMed ID: 30242640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
    Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
    Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of primary sjögren's syndrome-related interstitial lung disease: a retrospective cohort study.
    Amlani B; Elsayed G; Barvalia U; Kanne JP; Meyer KC; Sandbo N; Li Z; McCoy SS
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):136-147. PubMed ID: 33093777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome.
    Devauchelle-Pensec V; Morvan J; Rat AC; Jousse-Joulin S; Pennec Y; Pers JO; Jamin C; Renaudineau Y; Quintin-Roué I; Cochener B; Youinou P; Saraux A
    Clin Exp Rheumatol; 2011; 29(1):6-12. PubMed ID: 21345287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interstitial lung disease in primary Sjögren's syndrome.
    Roca F; Dominique S; Schmidt J; Smail A; Duhaut P; Lévesque H; Marie I
    Autoimmun Rev; 2017 Jan; 16(1):48-54. PubMed ID: 27682894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung involvement in primary Sjögren's syndrome: Correlation between high-resolution computed tomography score and mortality.
    Chen MH; Chou HP; Lai CC; Chen YD; Chen MH; Lin HY; Huang DF
    J Chin Med Assoc; 2014 Feb; 77(2):75-82. PubMed ID: 24342542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome.
    Jousse-Joulin S; Devauchelle-Pensec V; Cornec D; Marhadour T; Bressollette L; Gestin S; Pers JO; Nowak E; Saraux A
    Arthritis Rheumatol; 2015 Jun; 67(6):1623-8. PubMed ID: 25708147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Hatron PY; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Seror R; Pers JO; Meiners PM; Vissink A; Bootsma H; Nowak E; Saraux A
    Rheumatology (Oxford); 2015 Sep; 54(9):1699-708. PubMed ID: 25957440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
    Bowman SJ; Everett CC; O'Dwyer JL; Emery P; Pitzalis C; Ng WF; Pease CT; Price EJ; Sutcliffe N; Gendi NST; Hall FC; Ruddock SP; Fernandez C; Reynolds C; Hulme CT; Davies KA; Edwards CJ; Lanyon PC; Moots RJ; Roussou E; Giles IP; Sharples LD; Bombardieri M
    Arthritis Rheumatol; 2017 Jul; 69(7):1440-1450. PubMed ID: 28296257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiopoietin-like protein 2 as a novel marker for patients with primary Sjogren's syndrome-related interstitial lung disease.
    Shi L; Fu Q; Chen N; Liu R; Zheng Y
    Clin Exp Med; 2020 Aug; 20(3):393-399. PubMed ID: 32253547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dramatic reversal of lymphocytic interstitial pneumonitis in Sjögren's syndrome with rituximab.
    Swartz MA; Vivino FB
    J Clin Rheumatol; 2011 Dec; 17(8):454. PubMed ID: 22126805
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab and lupus interstitial lung disease: friend or foe?
    Efthimiou P; Kukar M; Hersh A
    Int J Rheum Dis; 2011 Feb; 14(1):e3-4. PubMed ID: 21303472
    [No Abstract]   [Full Text] [Related]  

  • 15. Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjögren's syndrome.
    Kakugawa T; Sakamoto N; Ishimoto H; Shimizu T; Nakamura H; Nawata A; Ito C; Sato S; Hanaka T; Oda K; Kido T; Miyamura T; Nakashima S; Aoki T; Nakamichi S; Obase Y; Saito K; Yatera K; Ishimatsu Y; Nakayama T; Korogi Y; Kawakami A; Tanaka Y; Mukae H
    Respir Med; 2018 Apr; 137():95-102. PubMed ID: 29605220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of cyclophosphamide on cytokines in patients with primary Sjögren's syndrome-associated interstitial lung disease].
    Mo HY; Wang LF; Xu J; Shi YH; Yang M; Zhou RH
    Zhonghua Jie He He Hu Xi Za Zhi; 2011 Jul; 34(7):495-9. PubMed ID: 22041773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of patients with primary Sjögren's syndrome associated interstitial lung disease and relevant features of disease progression.
    Zhang T; Yuan F; Xu L; Sun W; Liu L; Xue J
    Clin Rheumatol; 2020 May; 39(5):1561-1568. PubMed ID: 31902032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physical fatigue characterises patient experience of primary Sjögren's syndrome.
    Arends S; Meiners PM; Moerman RV; Kroese FG; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Clin Exp Rheumatol; 2017; 35(2):255-261. PubMed ID: 28032845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20).
    Devauchelle-Pensec V; Pennec Y; Morvan J; Pers JO; Daridon C; Jousse-Joulin S; Roudaut A; Jamin C; Renaudineau Y; Roué IQ; Cochener B; Youinou P; Saraux A
    Arthritis Rheum; 2007 Mar; 57(2):310-7. PubMed ID: 17330280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
    Gottenberg JE; Cinquetti G; Larroche C; Combe B; Hachulla E; Meyer O; Pertuiset E; Kaplanski G; Chiche L; Berthelot JM; Gombert B; Goupille P; Marcelli C; Feuillet S; Leone J; Sibilia J; Zarnitsky C; Carli P; Rist S; Gaudin P; Salliot C; Piperno M; Deplas A; Breban M; Lequerre T; Richette P; Ghiringhelli C; Hamidou M; Ravaud P; Mariette X;
    Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.